quinidine has been researched along with valproic acid in 27 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (14.81) | 18.7374 |
1990's | 3 (11.11) | 18.2507 |
2000's | 11 (40.74) | 29.6817 |
2010's | 8 (29.63) | 24.3611 |
2020's | 1 (3.70) | 2.80 |
Authors | Studies |
---|---|
Nezu, JI; Ohashi, R; Oku, A; Sai, Y; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
Topliss, JG; Yoshida, F | 1 |
Cha, SH; Endou, H; Fukushima , JI; Goya, T; Kanai, Y; Kobayashi, Y; Sekine, T | 1 |
Jolivette, LJ; Ward, KW | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Abraham, MH; Acree, WE; Ibrahim, A | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Bachmann, KA; Forney, RB; Jauregui, L; Martin, M; Nunlee, M; Schwartz, J | 1 |
Gal, J; Molitoris, BA; Nakata, LM; Sedman, AJ | 1 |
Hanano, M; Iga, T; Sawada, Y; Sugiyama, Y | 1 |
Müller, FO; Steyn, JM | 1 |
Hackett, T; Kelton, JG; Powers, P | 1 |
Bachmann, KA; Jauregui, L | 1 |
3 review(s) available for quinidine and valproic acid
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.
Topics: Animals; Antipyrine; Barbiturates; Biological Availability; Chlorpromazine; Diazepam; Drug Evaluation; Female; Half-Life; Humans; Kinetics; Male; Metabolic Clearance Rate; Pentazocine; Pharmaceutical Preparations; Phenylbutazone; Phenytoin; Propranolol; Quinidine; Rats; Species Specificity; Tissue Distribution; Tolbutamide; Valproic Acid; Warfarin | 1985 |
Drug-induced platelet destruction.
Topics: Binding Sites, Antibody; Blood Platelets; Cell Differentiation; Cell Migration Inhibition; Clot Retraction; Complement Fixation Tests; Gold; Heparin; Humans; Immunoglobulin G; Intradermal Tests; Platelet Aggregation; Platelet Factor 3; Prednisone; Quinidine; Ristocetin; Serotonin; Thrombocytopenia; Thromboembolism; Urea; Valproic Acid | 1982 |
1 trial(s) available for quinidine and valproic acid
Article | Year |
---|---|
Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo.
Topics: Administration, Oral; Adult; Antipyrine; Aryl Hydrocarbon Hydroxylases; Carbamazepine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Ethosuximide; Humans; Liver; Lorazepam; Male; Oxidoreductases, N-Demethylating; Phenobarbital; Phenytoin; Quinidine; Rifampin; Smoking; Theophylline; Valproic Acid | 1993 |
23 other study(ies) available for quinidine and valproic acid
Article | Year |
---|---|
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
Topics: Biological Transport, Active; Carnitine; Carrier Proteins; Cations; Cells, Cultured; Dose-Response Relationship, Drug; Embryo, Mammalian; Humans; Hydrogen-Ion Concentration; Kidney; Membrane Proteins; Organic Cation Transport Proteins; Sodium; Solute Carrier Family 22 Member 5; Stereoisomerism | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
Topics: Amino Acid Sequence; Animals; Carrier Proteins; Chromosome Mapping; Chromosomes, Human, Pair 11; Cloning, Molecular; Gene Library; Humans; Kidney Tubules, Proximal; Molecular Sequence Data; Oocytes; Organic Anion Transporters, Sodium-Independent; Sequence Homology, Amino Acid; Tissue Distribution; Transfection; Xenopus laevis | 2001 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The use of single sample clearance estimates to probe hepatic drug metabolism: handprinting the influence of cigarette smoking on human hepatic drug metabolism.
Topics: Antipyrine; Carbamazepine; Glucuronosyltransferase; Humans; Liver; Lorazepam; Male; Metabolic Clearance Rate; Microbodies; Microsomes, Liver; Mixed Function Oxygenases; Oxidoreductases; Pharmaceutical Preparations; Polycyclic Compounds; Quinidine; Smoking; Theophylline; Valproic Acid | 1990 |
Therapeutic drug monitoring in patients with chronic renal failure: evaluation of the Abbott TDx drug assay system.
Topics: Carbamazepine; Cross Reactions; Digoxin; Gentamicins; Humans; Immunoassay; Kidney Failure, Chronic; Lidocaine; Monitoring, Physiologic; Pharmaceutical Preparations; Phenobarbital; Phenytoin; Quinidine; Valproic Acid; Vancomycin | 1986 |
Comparative effects of two commercially available blood collection tubes on plasma concentrations of drugs.
Topics: Acebutolol; Blood Specimen Collection; Carbamazepine; Diazepam; Digoxin; Ethosuximide; Humans; Nordazepam; Penbutolol; Pharmaceutical Preparations; Propranolol; Quinidine; Salicylates; Time Factors; Valproic Acid; Warfarin | 1980 |